Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Clinical trial NCT01441596 · COMPLETED
Trial details
- NCT number
- NCT01441596
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-10-01
- Primary completion
- 2014-02-01
- Enrollment
- 121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.